AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update

By Dr. Matthew Watson

– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications

See the original post here:
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Related Post


categoriaGlobal News Feed commentoComments Off on AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update | dataAugust 19th, 2024

About...

This author published 5852 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research

Copyright :: 2024